Axogen Inc AXGN

$37.39 -2.53 (-6.34%)

Valuation

Market cap
2,146,179,000
Revenue TTM
$225,210,000
Net income TTM
$-15,700,000
PE ratio
0.00
Forward PE
—
Profit margin
-6.97%
Debt to equity
0.00

Trading

Volume
3,098,400
Avg volume
1,170,154
Day's range
$36.97 – $39.92
Shares out
53,762,000
Stochastic %K
4%
Beta
1.17
Analysts
Strong Sell
Price target
$53.20

Price

Company profile

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a ten...

Show more

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Industry
Medical Devices
Sector
Healthcare
Phone
386 462 6800
Website
https://www.axogeninc.com
Address
13631 Progress Boulevard, Suite 400, Alachua, United States

Latest news

Stocktwits

jlsnet22 Oct 2, 3:05 PM
$AXGN The market is a discounting mechanism. Perhaps the results for their prostatectomy nerve repair trial are not going to be positive. Hope that’s not the case.
2 replies
dustin1101 Oct 2, 2:09 PM
$AXGN transferring 150K to my 401k SDBA to buy more Monday.. though I'm guessing the price will be higher than this.
0 replies
dustin1101 Oct 2, 1:47 PM
$AXGN oh btw Lake Street 50 > 55 pt today.
0 replies
dustin1101 Oct 2, 1:45 PM
$AXGN so they paid 200M for a FDA cleared product that they project will add 36M in revs in the first full year at 73% gross margin (a lower p/s than the rest of the company is valued). Annd we're gonna sell down another $1.5 while the mkt is up. Ok.
1 replies
TheMarketsTheTarget Oct 2, 4:32 AM
$AXGN 33.50 gap
1 replies
dustin1101 Oct 1, 7:25 PM
$AXGN Very persistent seller vs a buyer that's plowed in $7M in mkt buys off the lower trendline here. Guess we'll see who runs out of gas first.
1 replies
dustin1101 Oct 1, 3:17 PM
$AXGN IMO when we see the 10yr start to trend down a bit we'll see a reversal here. Stuck in a pretty nasty downward channel. Fundamentals haven't changed. Quality bio is going to be a great hedge against the AI/tech giants and $$ should keep rotating. Being patient here and adding bits as we go. GL!
1 replies
dustin1101 Sep 30, 2:38 PM
$AXGN let's see if this move holds and we have a double bottom formed. So far it's being defended. Snagged 200 @41.92
1 replies